Sign up
Pharma Capital

ImmuPharma sees "significant opportunity" for lupus drug after phase III trial readout

The company revealed there had been "expressions of interest" in its lupus programme which it will explore
researcher filling a vial
The effectiveness among the 153 patients that got to the end of the course of treatment was 68.8%

ImmuPharma PLC (LON:IMM) said it believes there is a “significant opportunity” for its drug Lupuzor, used to treat autoimmune disease lupus, following the release of top-line results from a phase III trial.

The data revealed Lupuzor was more effective than the placebo (52.5% versus 44.6%). But because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of the study was not achieved. That 'end-point' was a statistically significant beneficial impact from Lupuzor.

This initial readout was based on 202 patients, including those who withdrew from the trial.

WATCH: Drug needs further analysis, City analyst

The effectiveness among the 153 that got to the end of the course of treatment was 68.8% (versus 59.2% for the placebo).

Importantly, in patients who had a certain type of lupus biomarker called anti-dsDNA autoantibodies, Lupuzor worked well when compared with the placebo. Added to that, 7.6% of this group went into full remission, while none did in the placebo group.

The safety profile remained good with no adverse effects

Chairman Tim McCarthy said: “Lupuzor has demonstrated, in this study, a superior response rate over placebo and its exceptional safety, giving it, we believe, a compelling product profile.

“Whilst we are disappointed at the high response in the placebo plus standard of care group that resulted in statistical significance not being reached between the two treatment groups, we believe Lupuzor has the potential to bring a much needed safe treatment to the millions of Lupus sufferers around the world.

“We look forward to providing our shareholders with further updates in due course."

Further investigation merited

ImmuPharma said it believes the top line results “provide evidence for the continued investigation into the development and commercialisation of Lupuzor”. It thinks the drug has the potential to offer patients and physicians a much needed effective and safe treatment for lupus.

Following requests from both investigators and patients, ImmuPharma has begun a further study. This will allow all patients who took part in the phase III trial to receive Lupuzor plus the ‘standard of care’ medication for six months in what’s called an open-label scheme.

The results will be gathered independent of the pivotal trial just completed.

The plan is to look at the full dataset before making a decision, but the company said there is demand for a new lupus treatment.

Expressions of interest

It also said there had been “expressions of interest” in the Lupuzor programme and the phase III study.

“ImmuPharma is in ongoing discussions with a number of larger pharmaceutical companies,” it added.

“The results of this study will now be shared with those potential commercial partners. There can be no certainty as to the outcome or timing of these discussions.”

The shares fell 76%.

----adds share price---

Ian_55ae0ddd437b7.jpg
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future IMM Company articles
View full IMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.